Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer

被引:262
|
作者
Zhu, Xinxin [1 ]
Lang, Jinghe [1 ]
机构
[1] Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Obstet & Gynecol, Beijing, Peoples R China
关键词
soluble; PD-1; PD-L1; tumor immunity; biomarker; CELL LUNG-CANCER; DEATH-LIGAND; PROGRAMMED DEATH-1; ANTITUMOR IMMUNITY; T-CELLS; HEPATOCELLULAR-CARCINOMA; CLINICAL-SIGNIFICANCE; POOR-PROGNOSIS; PD-1/PD-L1; BLOCKADE; CIRCULATING PD-L1;
D O I
10.18632/oncotarget.18311
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The membrane-bound molecules programmed death 1 (PD-1) and its ligand PD-L1 (PD-1/PD-L1) belong to the immune checkpoint pathway. PD-1 pathway downregulates effector T cells in immune response, thereby causing immune suppression. Recent studies have revealed that membrane-bound PD-1 and PD-L1 also have soluble forms. These soluble forms increase the complexity and diversity of the composition and function of the PD-1/PD-L1 signaling pathway. However, the exact roles of these molecules remain unknown. The objective of this systematic review was to elucidate the biological significance of soluble PD-1/PD-L1 in human cancers and evaluate whether they are potential diagnostic, therapeutic, or prognostic biomarkers. We expect to provide new clues for future research on soluble PD-1/PD-L1 pathway in human malignant tumors.
引用
收藏
页码:97671 / 97682
页数:12
相关论文
共 50 条
  • [1] Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
    Niu, Mengke
    Liu, Yiming
    Yi, Ming
    Jiao, Dechao
    Wu, Kongming
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [2] PD-1/PD-L1 in disease
    Kuol, Nyanbol
    Stojanovska, Lily
    Nurgali, Kulmira
    Apostolopoulos, Vasso
    IMMUNOTHERAPY, 2018, 10 (02) : 149 - 161
  • [3] PD-1/PD-L1 pathway: current researches in cancer
    Han, Yanyan
    Liu, Dandan
    Li, Lianhong
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (03): : 727 - 742
  • [4] Prognostic significance of PD-L1 and PD-L2 in breast cancer
    Baptista, Mauricio Z.
    Sarian, Luis Otavio
    Derchain, Sophie F. M.
    Pinto, Glauce A.
    Vassal, Jose
    HUMAN PATHOLOGY, 2016, 47 (01) : 78 - 84
  • [5] PD-1/PD-L1 as a prognostic factor in leukemia
    Rezaeeyan, Hadi
    Hassani, Seyedeh Nafiseh
    Barati, Mojgan
    Shahjahani, Mohammad
    Saki, Najmaldin
    JOURNAL OF HEMATOPATHOLOGY, 2017, 10 (01) : 17 - 24
  • [6] Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
    Meng, Xiangjiao
    Huang, Zhaoqin
    Teng, Feifei
    Xing, Ligang
    Yu, Jinming
    CANCER TREATMENT REVIEWS, 2015, 41 (10) : 868 - 876
  • [7] Measurement of soluble PD-1 and soluble PD-L1 as well as PD-L1 and PD-1 from perioperative patients with gastric carcinoma
    Wei, Hangzhi
    Wu, Fahong
    Mao, Yudong
    Zhang, Youcheng
    Leng, Guangxian
    Wang, Jia
    Zhang, Wei
    Wang, Tianwei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (04) : 331 - 345
  • [8] PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
    Bocanegra, Ana
    Blanco, Ester
    Fernandez-Hinojal, Gonzalo
    Arasanz, Hugo
    Chocarro, Luisa
    Zuazo, Miren
    Morente, Pilar
    Vera, Ruth
    Escors, David
    Kochan, Grazyna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (16) : 1 - 17
  • [9] Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors
    Fan, Yangwei
    Ma, Ke
    Wang, Chuying
    Ning, Jing
    Hu, Yuan
    Dong, Danfeng
    Dong, Xuyuan
    Geng, Qianqian
    Li, Enxiao
    Wu, Yinying
    ONCOTARGETS AND THERAPY, 2016, 9 : 6075 - 6082
  • [10] Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
    Zhuang, Yuan
    Liu, Chang
    Liu, Jiaqing
    Li, Guang
    ONCOTARGETS AND THERAPY, 2020, 13 : 83 - 94